Kymera Therapeutics (KYMR) Non-Current Assets (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Non-Current Assets of $991.6 million for Q1 2026, up 137.58% year-over-year from $417.4 million in Q1 2025, and up 13.77% quarter-over-quarter from $871.6 million in Q4 2025.
Kymera Therapeutics (KYMR) Non-Current Assets (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Non-Current Assets for 8 consecutive years, with $991.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 137.58% year-over-year to $991.6 million; the TTM figure through Mar 2026 stood at $2.8 billion (up 71.91% YoY), while the FY2025 annual figure was $871.6 million, up 86.33% from the prior year.
- Non-Current Assets climbed to $991.6 million in Q1 2026 per KYMR's latest filing, from $871.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $991.6 million in Q1 2026 and bottomed at $120.7 million in Q2 2022.
- Historically, Non-Current Assets has averaged $361.7 million across 5 years, with a median of $300.6 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Assets slipped 7.23% — and 2024, when it surged 174.44%.
- Kymera Therapeutics' Non-Current Assets stood at $183.7 million in 2022, then retreated by 7.23% to $170.4 million in 2023, then soared by 174.44% to $467.8 million in 2024, then surged by 86.33% to $871.6 million in 2025, then grew by 13.77% to $991.6 million in 2026.
- Business Quant data shows KYMR's Non-Current Assets at $991.6 million in Q1 2026, $871.6 million in Q4 2025, and $573.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 908.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 908.18 Mn |
| Mar 31, 2026 | 991.58 Mn |
| Dec 31, 2025 | 871.60 Mn |
| Sep 30, 2025 | 573.75 Mn |
| Jun 30, 2025 | 402.74 Mn |
| Mar 31, 2025 | 417.36 Mn |
| Dec 31, 2024 | 467.77 Mn |
| Sep 30, 2024 | 466.13 Mn |
| Jun 30, 2024 | 300.61 Mn |
| Mar 31, 2024 | 331.00 Mn |
| Dec 31, 2023 | 170.44 Mn |
| Sep 30, 2023 | 176.68 Mn |
| Jun 30, 2023 | 196.54 Mn |
| Mar 31, 2023 | 202.36 Mn |
| Dec 31, 2022 | 183.72 Mn |
| Sep 30, 2022 | 144.45 Mn |
| Jun 30, 2022 | 120.65 Mn |
| Mar 31, 2022 | 131.68 Mn |
| Dec 31, 2021 | 154.63 Mn |
| Sep 30, 2021 | 98.72 Mn |